Story

On air. The free wire runs 15 minutes behind live. See pricing

World, crypto, finance and tech news, scored for impact.

MarketsSEC EDGAR SCHEDULE 13GFiled 5 days ago

Drugs Made In America Acquisition II Corp.: Karpus Management, Inc. discloses a stake of more than 5% (Schedule 13G)

Open the sourceReported by SEC EDGAR SCHEDULE 13G, sec.gov, 13 November 2026, by SEC EDGAR SCHEDULE 13G

Not investment advice. Muhabbit scores how much a story may matter, not which way to trade.

Karpus Management disclosed a stake exceeding 5% in Drugs Made In America Acquisition II Corp. via a Schedule 13G filing with the SEC (accession 0001072613-26-000875). The exact share count and percentage were not specified in the filing headline. The disclosure signals new institutional interest in the special purpose acquisition company. Investors will watch for further 13G/13D amendments and any updates on the SPAC's merger timeline.

Muhabbit's AI wrote this summary in its own words from SEC EDGAR SCHEDULE 13G's report. It can get details wrong, so check the source.

Named in this story

Drugs Made In America Acquisition II Corp., Karpus Management, Inc.